ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / VRCA / dividends
CTOR (34) RNTX (38) NMAD (31) HRTX (34) ⌘ Pro Terminal β†’

Verrica Pharmaceuticals Inc. (VRCA) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.21 -4.18% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.18

Verrica Pharmaceuticals Inc. (VRCA) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $55.1M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VRCA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is VRCA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.21 (-4.18% 1D, market cap $55.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VRCA ranks #727 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does VRCA compare to CTOR and RNTX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRCA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, CTOR (Citius Oncology Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $55.2M) and RNTX (Rein Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $54.8M). Among the 5-stock peer group, VRCA leads on earnings multiple (N/A) while VRCA leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VRCA?
β–Ό

Per VRCA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001660334), Verrica Pharmaceuticals Inc. generated $35.6M in revenue (+370.2% YoY), -$17.9M in net income, and -$17.6M in free cash flow against $47.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.18 (-0.94%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (6)Whales (3)SEC (11)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
$10 Bull$3 Base$2 Bear
πŸ“¬ FREE VRCA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for VRCA)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY VRCA SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (22% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 31.3 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
40
Grade D$3.58-3.1% Next Q
Q2 (-2Q)
37
Grade E$3.47+0% Next Q
Q3 (-1Q)
35
Grade E$3.47-7.5% Next Q
Current
32
Grade E$3.21-9.2% Hist 90D Ξ±
Trajectory: D (40) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a VRCA Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While VRCA currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.34) and Max Pain ($3.37) forces dealer call-delta covering toward $10.31.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRCAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œVRCA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $45,269

Est. Year-10 Shareholder Yield: $815/yr
$11.6K
Yr 1
$13.5K
Yr 2
$15.7K
Yr 3
$18.3K
Yr 4
$21.3K
Yr 5
$24.7K
Yr 6
$28.8K
Yr 7
$33.5K
Yr 8
$38.9K
Yr 9
$45.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VRCA)

  • βœ“Walkthrough of VRCA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
VRCA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.17%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $3.35H $3.35L $3.21C $3.21VOL 55.8K
RES: $4.67SUP: $3.02SMA50: $4.34SMA200: $5.57
$8.87$7.34$5.80$4.27$2.73RES $4.67SUP $3.02$3.212026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VRCA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ VRCA Butterfly Map β†’ + Track VRCA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +370.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VRCA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for VRCA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VRCA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRCA)

Health Care Rank #727 of 1015 βš”οΈ CTOR vs VRCA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (VRCA vs. CTOR, RNTX, NMAD, HRTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Verrica Pharmaceuticals Inc. (VRCA) ranks #727 by composite RQD confidence (32/100, grade E) and #726 by equity capitalization ($55.1M). Within this direct 5-issuer industry benchmark cohort, VRCA leads on earnings valuation at N/A trailing P/E, while VRCA leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. RNTX currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with VRCA at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VRCA ACTIVE
Verrica Pharmaceuticals Inc.
E 32/100 β€” β€” -35.0% -4.18% $55.1M Benchmark Subject
CTOR
Citius Oncology Inc.
E 34/100 β€” β€” -35.0% +7.24% $55.2M /ctor-vs-vrca β†’
RNTX
Rein Therapeutics Inc.
D- 38/100 β€” β€” -35.0% -5.16% $54.8M /rntx-vs-vrca β†’
NMAD
Nomad Power Solutions Inc.
E 31/100 β€” β€” -35.0% -2.53% $55.9M /nmad-vs-vrca β†’
HRTX
Heron Therapeutics Inc.
E 34/100 β€” 73.3% -35.0% +6.27% $56.0M /hrtx-vs-vrca β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001660334 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verrica Pharmaceuticals Inc. (VRCA) reported GAAP revenue of $35.6M (+370.2% vs. FY2024 revenue of $7.6M , and +594.3% cumulative change since FY2023) , GAAP net income of -$17.9M, operating cash flow of -$17.6M, and free cash flow of -$17.6M (+71.1% YoY). On the balance sheet, VRCA closed FY2025 with $47.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $35.6M -$17.9M -$17.6M -$17.6M $47.1M β€”
FY2024 (FY) 2024-12-31 $7.6M -$76.6M -$60.9M -$61.0M $54.1M β€”
FY2023 (FY) 2023-12-31 $5.1M -$67.0M -$38.6M -$38.6M β€” β€”

3. VRCA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VRCA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.21 (-4.18% 1D, market cap $55.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VRCA ranks #727 in composite RQD confidence.

How does VRCA compare to CTOR and RNTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRCA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, CTOR (Citius Oncology Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $55.2M) and RNTX (Rein Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $54.8M). Among the 5-stock peer group, VRCA leads on earnings multiple (N/A) while VRCA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VRCA?

Per VRCA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001660334), Verrica Pharmaceuticals Inc. generated $35.6M in revenue (+370.2% YoY), -$17.9M in net income, and -$17.6M in free cash flow against $47.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VRCA trading relative to its 50-day, 200-day, and 52-week technical levels?

VRCA last traded at $3.21 (-4.18% on volume of 55,797 shares), positioning the stock -26.04% below its 50-day simple moving average ($4.34) and -42.37% below its 200-day simple moving average ($5.57). Across its 52-week range of $3.21 to $9.82, VRCA sits at the 0.0% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($2.81 to $3.61).

Direct Sub-Reports: VRCA RQD Cockpit VRCA 12M Forecast VRCA Earnings & Move VRCA Dividends & DRIP VRCA Insiders & 13F VRCA Whale Options VRCA Profit Sankey VRCA News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

VRCA β€” Verrica Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Verrica Pharmaceuticals Inc. (VRCA) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.21 (-4.18% 1D, market capitalization $55.1M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -34.2%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Verrica Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B. The company's products, customers, and revenue model are not described in detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Verrica Pharmaceuticals Inc. (VRCA) reported $35.6M in annual revenue (up from $7.6M in FY2024, +370.2% YoY) and -$17.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.1M revenue, -$67.0M net income) through FY2025, VRCA scaled operating cash flow to -$17.6M and free cash flow to -$17.6M, backed by $47.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.21 – $9.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -34.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VRCA carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can VRCA sustain or expand its -34.2% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $35.6M and free cash flow of -$17.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VRCA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VRCA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Verrica Pharmaceuticals Inc. (VRCA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to VRCA Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VRCA Bull vs. Bear Conversation Board β€” What's Your Call at $3.21?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VRCA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VRCA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $4.29 (+28.1%)
πŸ“Œ Pinned Debate

Revenue grew from $5.1M in FY 2023 to $35.6M in FY 2025 while the net loss narrowed to -$17.9M, and the news feed reports unlocked non-

Picked up a starter position in VRCA in my $100K Virtual Cash book at $3.35. Revenue grew from $5.1M in FY 2023 to $35.6M in FY 2025 while the net loss narrowed to -$17.9M, and the news feed reports unlocked non-dilutive credit facility funding.. Trading inside a $3.25–$9.82 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 πŸ‚ BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $2.85 (-14.9%)
Spot @ $3.35

ROIC of -35%, a 0% FCF yield, and a Roarable Sell verdict with a 44 RQD score indicate weak cash generation and negative distribution s

Here is the bear case nobody on the bull side wants to address on VRCA: ROIC of -35%, a 0% FCF yield, and a Roarable Sell verdict with a 44 RQD score indicate weak cash generation and negative distribution signals.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE